Intech Investment Management LLC Increases Stake in Edwards Lifesciences Corporation $EW

Intech Investment Management LLC lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 49.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 56,756 shares of the medical research company’s stock after purchasing an additional 18,843 shares during the period. Intech Investment Management LLC’s holdings in Edwards Lifesciences were worth $4,414,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. True Wealth Design LLC grew its stake in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares during the last quarter. NewSquare Capital LLC lifted its stake in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 164 shares during the period. Rakuten Securities Inc. grew its position in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Finally, Steigerwald Gordon & Koch Inc. bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $30,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the transaction, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. This trade represents a 53.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 67,804 shares of company stock worth $5,711,242 over the last ninety days. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Up 0.7%

Shares of EW opened at $86.47 on Monday. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average price is $82.74 and its 200-day moving average price is $81.27. The firm has a market capitalization of $50.22 billion, a price-to-earnings ratio of 47.25, a PEG ratio of 2.26 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on EW. Royal Bank Of Canada increased their price objective on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. Evercore reissued an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 5th. Sanford C. Bernstein reissued a “market perform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, November 3rd. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, Canaccord Genuity Group set a $87.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.